This is a very speculative biotech that has interesting potential.
Predictive Technology Group, Inc. (PRED)
From S.A. Advisory
Predictive Technology Group, Inc. was our pick for 2020 and it turned out to be a major loser!
Most would have moved on to greener pastures. Our greener pastures will house PRED for our stock pick of the year for 2021. Many things went wrong, and of course, COVID changed everything. The delay in release of the company’s Endometriosis & Infertility test and slowdown of stem cells sales resulted from massive clinic closures.
The shares currently trade on the “grey’s” because of SEC paranoia. The listing is currently being addressed and the company will get off on its own or merge into another entity.
The company remains fully reporting/compliant and its auditor is the #1 firm in the USA (Deloitte & Touche).
Predictive’s Board of Directors remains solid and surely resembles Fortune 100 management. PRED still has a collaborative relationship with Thermal Fisher (TMO) and a developmental collaborative relationship with Atrin (cancer therapy). At present, PRED has been ramping-up its COVID 19 saliva testing (6 days/wk) and stem cells sales continues to recover.
Most of PRED’s assets are not being valued! The company has a genetic library of 300k DNA samples (serious maternal/neonatal disorder worth at least $300 each and of that number 45k are DNA sequenced worth $1,000.00 each or est. of $122 million). PRED is not being valued for Endo and Infertility kits, CLIA lab, patents, management, or other corporate relationships.
The current market-cap is tiny and does not even attempt to measure the discounted valued and future potential that PRED may offer investors. Looking at current share price is a huge error. We believe investors have the opportunity to 10-30X their initial investment, even though some might be averaging down from last year’s price recommendation. The current listing has truly depressed this cutting edge biotech women’s health Covid test company.
Take some time and review the size of the industrial segments that the company participates in (Endometriosis ($2 billion), Stem cells ($2.75 billion), Cancer research (specific to Atrin, $4.7 billion), Infertility ($2.4 billion), and Covid 19 testing (worldwide $20 billion).
We rate PRED with our strongest buy recommendation and truly believe that our stock pick for 2021 will take the #1 spot within the 1-year time period.
William Velmer, S.A. Advisory, saadvisory.com, 949-922-9986, January 3, 2021